Botulinum toxin for spasticity: a case for change to the Pharmaceutical Benefits Scheme

Anupam Datta Gupta and David H Wilson
Med J Aust 2018; 208 (9): . || doi: 10.5694/mja17.00841
Published online: 29 January 2018

Current permissible use of botulinum toxin in Australia does not match newer understandings of human impairment and functioning

The bacterium Clostridium botulinum was first identified in 1895 and, in the 1950s, was first injected into a hyperactive muscle, causing flaccid paralysis by blocking the release of the neurotransmitter acetylcholine from motor nerve endings. However, the therapeutic use of botulinum toxin only became common after 1989, when it was approved for use for strabismus, and then in 2001, when it was synthesised and approved for use as a cosmetic treatment in Canada. In 2017, the idea of paralysing the muscles of the brow and face with a powerful neurotoxin for cosmetic reasons is now widely accepted, or at least conceptually understood, because of frequent reference to the popular procedure in the media.

  • Queen Elizabeth Hospital, Adelaide, SA



We thank Barbara Brougham for editing earlier versions of this article.

Competing interests:

No relevant disclosures.

  • 1. Sheean GL. Botulinum toxin should be first line treatment for post stroke spasticity. J Neurol Neurosurg Psychiatry 2009; 80: 359.
  • 2. Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355: 818-828.
  • 3. World Health Organization. The International Classification of Functioning, Disability and Health. Geneva: WHO 2001.
  • 4. World Health Organization. World report on disability. Geneva: WHO, 2011. (viewed Dec 2017).
  • 5. Esquenazi A. The human and economic burden of post stroke spasticity and muscle overactivity. J Clin Outcomes Manag 2011; 18: 607-614.
  • 6. Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological, humanistic and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat 2014; 10: 111-122.
  • 7. Ashour R, Tintner R, Jankovic J. Striatal deformities of hand and foot in Parkinson’s disease. Lancet Neurol 2005; 4: 423-431.
  • 8. Lundstrom E, Sits A, Borg J, Terent A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010; 41: 319-324.
  • 9. Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol 2006; 13: 27-34.
  • 10. Montané E, Vallano A, Laporte JR. Oral antispastic drugs in non-progressive neurologic diseases: a systematic review. Neurology 2004; 63(8): 1357-1363.
  • 11. Teasell R, Foley N, Pereira S, et al. Evidence to practice: botulinum toxin in the treatment of spasticity post stroke. Top Stroke Rehabil 2012; 19: 115-121.
  • 12. Delgad MR, Tilton A, Russman B, et al. Abotulinumtoxin A for equinus foot deformity in cerebral palsy: a randomised controlled trial. Paediatrics 2016; 137: e20152830.
  • 13. Gracies JM, Esquenazi A, Brashear A, et al. Efficacy and Safety of abobotulinumtoxinA in spastic lower limb - Randomized trial and extension. Neurology 2017; 89: 1-9.
  • 14. Sheean G. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 2001; 14: 771-776.
  • 15. Wein T, Dimitrova R, Esquenazi A, et al. Onabotulinum toxin A treatment in adult patients with post-stroke lower limb spasticity: results from a double-blind placebo- controlled, phase 3 clinical trial. Int J Stroke 2015; 10: 5.
  • 16. Rehabilitation Medicine Society of Australia and New Zealand. Position statement on the therapeutic use of botulinum toxin in rehabilitation medicine for spasticity and dystonia. (viewed Nov 2017).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.